keyword
MENU ▼
Read by QxMD icon Read
search

HIV testing

keyword
https://www.readbyqxmd.com/read/29149914/testing-the-effectiveness-of-a-motivational-interviewing-based-brief-intervention-for-substance-use-as-an-adjunct-to-usual-care-in-community-based-aids-service-organizations-study-protocol-for-a-multisite-randomized-controlled-trial
#1
Bryan R Garner, Heather J Gotham, Stephen J Tueller, Elizabeth L Ball, David Kaiser, Patricia Stilen, Kathryn Speck, Denna Vandersloot, Traci R Rieckmann, Michael Chaple, Erika G Martin, Steve Martino
BACKGROUND: In 2010, the first comprehensive National HIV/AIDS Strategy for the United States was released and included three goals: (1) reducing the number of people who become infected with HIV, (2) increasing access to care and improving health outcomes for people living with HIV, and (3) reducing HIV-related health disparities and health inequities. In 2013, as part of its effort to help address the National HIV/AIDS Strategy, the National Institute on Drug Abuse (NIDA) funded a type 2 effectiveness-implementation hybrid trial titled the Substance Abuse Treatment to HIV Care (SAT2HIV) Project...
November 17, 2017: Addiction Science & Clinical Practice
https://www.readbyqxmd.com/read/29149909/testing-the-implementation-and-sustainment-facilitation-isf-strategy-as-an-effective-adjunct-to-the-addiction-technology-transfer-center-attc-strategy-study-protocol-for-a-cluster-randomized-trial
#2
Bryan R Garner, Mark Zehner, Mathew R Roosa, Steve Martino, Heather J Gotham, Elizabeth L Ball, Patricia Stilen, Kathryn Speck, Denna Vandersloot, Traci R Rieckmann, Michael Chaple, Erika G Martin, David Kaiser, James H Ford
BACKGROUND: Improving the extent to which evidence-based practices (EBPs)-treatments that have been empirically shown to be efficacious or effective-are integrated within routine practice is a well-documented challenge across numerous areas of health. In 2014, the National Institute on Drug Abuse funded a type 2 effectiveness-implementation hybrid trial titled the substance abuse treatment to HIV Care (SAT2HIV) Project. Aim 1 of the SAT2HIV Project tests the effectiveness of a motivational interviewing-based brief intervention (MIBI) for substance use as an adjunct to usual care within AIDS service organizations (ASOs) as part of its MIBI Experiment...
November 17, 2017: Addiction Science & Clinical Practice
https://www.readbyqxmd.com/read/29149194/understanding-linkage-to-care-with-hiv-self-test-approach-in-lusaka-zambia-a-mixed-method-approach
#3
Jenala Chipungu, Samuel Bosomprah, Arianna Zanolini, Harsha Thimurthy, Roma Chilengi, Anjali Sharma, Charles B Holmes
INTRODUCTION: HIV self-testing (HIVST) is a novel approach designed to assist in achieving the goal of at least 90% of the population that learn their HIV status. A self-test user with a positive test is required to visit a clinic to link into HIV care, yet little is known about patient preferences for linkage strategies. We examined the intention to link to care amongst potential HIVST users and the suitability of three linkage to care strategies in Lusaka Province, Zambia. METHODS: We conducted a representative cross sectional survey of 1,617 individuals aged 16-49 years old in Lusaka Province...
2017: PloS One
https://www.readbyqxmd.com/read/29146139/how-to-prevent-renal-cachexia-a-clinical-randomized-pilot-study-testing-oral-supplemental-nutrition-in-hemodialysis-patients-with-and-without-human-immunodeficiency-virus-infection
#4
Michael Zilles, Christoph Betz, Oliver Jung, Stefan Gauer, Renate Hammerstingl, Astrid Wächtershäuser, Thomas J Vogl, Helmut Geiger, Aida Asbe-Vollkopf, Rainer U Pliquett
OBJECTIVE: End-stage renal disease associates with catabolism and sarcopenia. Hypothetically, peroral supplemental nutrition over 6 months prevents catabolism in hemodialysis patients. DESIGN: Prospective randomized pilot study (ClinicalTrials.gov Identifier: NCT00687050). SUBJECTS: Twenty-three hemodialysis patients (15 males and 7 females) with or without human immunodeficiency virus (HIV) infection of 2 ambulatory hemodialysis centers...
November 14, 2017: Journal of Renal Nutrition
https://www.readbyqxmd.com/read/29145807/durability-of-switch-regimens-based-on-rilpivirine-or-on-integrase-inhibitors-both-in-association-with-tenofovir-and-emtricitabine-in-hiv-infected-virologically-suppressed-patients
#5
Nicola Gianotti, Andrea Poli, Silvia Nozza, Laura Galli, Nadia Galizzi, Marco Ripa, Marco Merli, Alessia Carbone, Vincenzo Spagnuolo, Adriano Lazzarin, Antonella Castagna
BACKGROUND: Switch strategies based on rilpivirine/tenofovir/emtricitabine or on an integrase inhibitor (InSTI) plus tenofovir/emtricitabine have never been compared in randomized clinical trials. The main aim of the study was to investigate the durability of these two switch regimens in virologically suppressed, HIV-infected patients. METHODS: Retrospective analysis of patients who started rilpivirine or an InSTI (both with tenofovir and emtricitabine) with <50 HIV-RNA copies/mL and had at least one HIV-RNA assessed while receiving the study regimen...
November 16, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29145741/a-cohort-approach-to-real-time-detection-of-acute-hiv-infections-among-people-who-inject-drugs-in-st-petersburg-russia
#6
Olga Toussova, Andrei Kozlov, Sergei Verevochkin, Kathryn Lancaster, Alla Shaboltas, Alexey Masharsky, Elena Dukhovlinova, William C Miller, Irving Hoffman
OBJECTIVES: To detect acute HIV infections (AHI) in real time among people who inject drugs (PWID) in St. Petersburg, Russia and to test the feasibility of this approach. DESIGN: Prospective cohort study. METHODS: 100 seronegative or acutely HIV-infected at screening PWID were enrolled and followed until the end of the 12 month pilot period. Each participant was evaluated, tested and counseled for HIV monthly. Two HIV tests were used: HIV antibody and HIV RNA PCR...
November 16, 2017: AIDS Research and Human Retroviruses
https://www.readbyqxmd.com/read/29145597/laboratory-testing-of-a-cohort-of-commercially-insured-users-of-hiv-preexposure-prophylaxis-in-the-united-states-2011-2015
#7
Ya-Lin A Huang, Guoyu Tao, Taraz Samandari, Karen W Hoover
To ensure the health and safety of persons taking antiretroviral medication for HIV preexposure prophylaxis (PrEP), CDC guidelines recommend initial and follow-up laboratory testing. We assessed the rates of recommended testing using a commercial insurance claims database. Before taking PrEP, 45% of users were tested for HIV, 31% for creatinine, 55% for syphilis, 43% for chlamydia/gonorrhea, and 38% for hepatitis B. By 6 months after PrEP initiation, 38% were tested for HIV, 37% for creatinine, 49% for syphilis, and 39% for chlamydia/gonorrhea...
November 14, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29145519/stigmatizing-attitudes-toward-people-living-with-hiv-among-general-adult-thai-population-results-from-the-5th-thai-national-health-examination-survey-nhes
#8
Kriengkrai Srithanaviboonchai, Suwat Chariyalertsak, Jiraluck Nontarak, Sawitri Assanangkornchai, Pattapong Kessomboon, Panwadee Putwatana, Surasak Taneepanichskul, Wichai Aekplakorn
BACKGROUND: HIV-related stigma and discrimination is a significant driver of the HIV and AIDS epidemic. UNAIDS encourages all nations to monitor progress toward elimination of this problem. This study measured the level of stigmatizing attitudes toward people living with HIV (PLHIV) among Thai adults in the general population using recommended global tools. METHODS: Data from the 5th National Health Examination Survey, conducted in 2014 were used. The survey utilized six questions recommended by the Global Stigma and Discrimination Indicator Working Group and was administered to participants aged 20-59 years old...
2017: PloS One
https://www.readbyqxmd.com/read/29145454/reduction-of-hiv-associated-excess-mortality-by-antiretroviral-treatment-among-tuberculosis-patients-in-kenya
#9
Dickens O Onyango, Courtney M Yuen, Kevin P Cain, Faith Ngari, Enos O Masini, Martien W Borgdorff
BACKGROUND: Mortality from TB continues to be a global public health challenge. TB ranks alongside Human Immunodeficiency Virus (HIV) as the leading infectious causes of death globally. HIV is a major driver of TB related morbidity and mortality while TB is the leading cause of mortality among people living with HIV/AIDS. We sought to determine excess mortality associated with HIV and the effect of antiretroviral therapy on reducing mortality among tuberculosis patients in Kenya. METHODS: We conducted a retrospective analysis of Kenya national tuberculosis program data of patients enrolled from 2013 through 2014...
2017: PloS One
https://www.readbyqxmd.com/read/29145422/missense-mutation-at-cldn8-associated-with-a-high-plasma-interferon-gamma-inducible-protein-10-level-in-methadone-maintained-patients-with-urine-test-positive-for-morphine
#10
Tung-Hsia Liu, Ren-Hua Chung, Sheng-Chang Wang, Chiu-Ping Fang, Hsiao-Hui Tsou, Chia-Lung Shih, Hsiang-Wei Kuo, Yun Wang, Yu-Li Liu
We previously reported a high plasma chemokine interferon gamma-inducible protein 10 (IP-10) level and prolonged electrocardiography QT-interval in methadone maintenance treatment (MMT) patients with HIV or HCV infection. The purpose of this study was to evaluate the genetic association of high plasma IP-10 level in the MMT patients. The gene-based and pathway-based association analyses were conducted using a genome-wide association study dataset in 344 MMT patients for identifying genes and pathways associated with plasma IP-10 level...
2017: PloS One
https://www.readbyqxmd.com/read/29143681/economic-evaluation-of-hcv-testing-approaches-in-low-and-middle-income-countries
#11
REVIEW
Jake R Morgan, Maria Servidone, Philippa Easterbrook, Benjamin P Linas
BACKGROUND: Hepatitis C virus (HCV) infection represents a major public health burden with diverse epidemics worldwide, but at present, only a minority of infected persons have been tested and are aware of their diagnosis. The advent of highly effective direct acting antiviral (DAA) therapy, which is becoming available at increasingly lower costs in low and middle income countries (LMICs), represents a major opportunity to expand access to testing and treatment. However, there is uncertainty as to the optimal testing approaches and who to prioritize for testing...
November 1, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29143676/the-future-of-viral-hepatitis-testing-innovations-in-testing-technologies-and-approaches
#12
REVIEW
Rosanna W Peeling, Debrah I Boeras, Francesco Marinucci, Philippa Easterbrook
A large burden of undiagnosed hepatitis virus cases remains globally. Despite the 257 million people living with chronic hepatitis B virus infection, and 71 million with chronic viraemic HCV infection, most people with hepatitis remain unaware of their infection. Advances in rapid detection technology have created new opportunities for enhancing access to testing and care, as well as monitoring of treatment. This article examines a range of other technological innovations that can be leveraged to provide more affordable and simplified approaches to testing for HBV and HCV infection and monitoring of treatment response...
November 1, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29143673/the-heptestcontest-a-global-innovation-contest-to-identify-approaches-to-hepatitis-b-and-c-testing
#13
Joseph D Tucker, Kathrine Meyers, John Best, Karyn Kaplan, Razia Pendse, Kevin A Fenton, Isabelle Andrieux-Meyer, Carmen Figueroa, Pedro Goicochea, Charles Gore, Azumi Ishizaki, Giten Khwairakpam, Veronica Miller, Antons Mozalevskis, Michael Ninburg, Ponsiano Ocama, Rosanna Peeling, Nick Walsh, Massimo G Colombo, Philippa Easterbrook
BACKGROUND: Innovation contests are a novel approach to elicit good ideas and innovative practices in various areas of public health. There remains limited published literature on approaches to deliver hepatitis testing. The purpose of this innovation contest was to identify examples of different hepatitis B and C approaches to support countries in their scale-up of hepatitis testing and to supplement development of formal recommendations on service delivery in the 2017 World Health Organization hepatitis B and C testing guidelines...
November 1, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29143625/trends-in-hepatitis-b-virus-testing-practices-and-management-in-hiv-clinics-across-sub-saharan-africa
#14
REVIEW
Patrick A Coffie, Matthias Egger, Michael J Vinikoor, Marcel Zannou, Lameck Diero, Akouda Patassi, Mark H Kuniholm, Moussa Seydi, Guillaume Bado, Ponsiano Ocama, Monique I Andersson, Eugène Messou, Albert Minga, Philippa Easterbrook, Kathryn Anastos, François Dabis, Gilles Wandeler
BACKGROUND: Approximately 8% of HIV-infected individuals are co-infected with hepatitis B virus (HBV) in sub-Saharan Africa (SSA). Knowledge of HBV status is important to guide optimal selection of antiretroviral therapy (ART) and monitor/prevent liver-related complications. We describe changes in testing practices and management of HBV infection over a 3-year period in HIV clinics across SSA. METHODS: A medical chart review was conducted in large urban HIV treatment centers in Côte d'Ivoire (3 sites), Benin, Burkina Faso, Cameroon, Kenya, Senegal, South Africa, Togo, Uganda and Zambia (1 site each)...
November 1, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29143620/optimising-diagnosis-of-viraemic-hepatitis-c-infection-the-development-of-a-target-product-profile
#15
Elena Ivanova Reipold, Philippa Easterbrook, Alessandra Trianni, Nivedha Panneer, Douglas Krakower, Stefano Ongarello, Teri Roberts, Veronica Miller, Claudia Denkinger
BACKGROUND: The current low access to virological testing to confirm chronic viraemic HCV infection in low- and middle-income countries (LMIC) is limiting the rollout of hepatitis C (HCV) care. Existing tests are complex, costly and require sophisticated laboratory infrastructure. Diagnostic manufacturers need guidance on the optimal characteristics a virological test needs to have to ensure the greatest impact on HCV diagnosis and treatment in LMIC. Our objective was to develop a target product profile (TPP) for diagnosis of HCV viraemia using a global stakeholder consensus-based approach...
November 1, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29143619/diagnostic-accuracy-of-tests-to-detect-hepatitis-b-surface-antigen-a-systematic-review-of-the-literature-and-meta-analysis
#16
Ali Amini, Olivia Varsaneux, Helen Kelly, Weiming Tang, Wen Chen, Debrah I Boeras, Jane Falconer, Joseph D Tucker, Roger Chou, Azumi Ishizaki, Philippa Easterbrook, Rosanna W Peeling
BACKGROUND: Chronic Hepatitis B Virus (HBV) infection is characterised by the persistence of hepatitis B surface antigen (HBsAg). Expanding HBV diagnosis and treatment programmes into low resource settings will require high quality but inexpensive rapid diagnostic tests (RDTs) in addition to laboratory-based enzyme immunoassays (EIAs) to detect HBsAg. The purpose of this review is to assess the clinical accuracy of available diagnostic tests to detect HBsAg to inform recommendations on testing strategies in 2017 WHO hepatitis testing guidelines...
November 1, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29143615/diagnostic-accuracy-of-tests-to-detect-hepatitis-c-antibody-a-meta-analysis-and-review-of-the-literature
#17
Weiming Tang, Wen Chen, Ali Amini, Debi Boeras, Jane Falconer, Helen Kelly, Rosanna Peeling, Olivia Varsaneux, Joseph D Tucker, Philippa Easterbrook
BACKGROUND: Although direct-acting antivirals can achieve sustained virological response rates greater than 90% in Hepatitis C Virus (HCV) infected persons, at present the majority of HCV-infected individuals remain undiagnosed and therefore untreated. While there are a wide range of HCV serological tests available, there is a lack of formal assessment of their diagnostic performance. We undertook a systematic review and meta-analysis to evaluate he diagnostic accuracy of available rapid diagnostic tests (RDT) and laboratory based EIA assays in detecting antibodies to HCV...
November 1, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29143609/survey-of-programmatic-experiences-and-challenges-in-delivery-of-hepatitis-b-and-c-testing-in-low-and-middle-income-countries
#18
Azumi Ishizaki, Julie Bouscaillou, Niklas Luhmann, Stephanie Liu, Raissa Chua, Nick Walsh, Sarah Hess, Elena Ivanova, Teri Roberts, Philippa Easterbrook
BACKGROUND: There have been few reports on programmatic experience of viral hepatitis testing and treatment in resource-limited settings. To inform the development of the 2017 World Health Organization (WHO) viral hepatitis testing guidance and in particular the feasibility of proposed recommendations, we undertook a survey across a range of organisations engaged with hepatitis testing in low- and middle-income countries (LMICs). Our objective was to describe current hepatitis B and C testing practices across a range of settings in different countries, as well as key barriers or challenges encountered and proposed solutions to promote testing scale-up...
November 1, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29143565/hiv-1-resistance-rarely-observed-in-subjects-using-darunavir-once-daily-regimens-across-clinical-studies
#19
Erkki Lathouwers, Eric Y Wong, Donghan Luo, Sareh Seyedkazemi, Sandra De Meyer, Kimberley Brown
BACKGROUND: Darunavir 800 mg once daily (QD) is indicated for HIV-1-infected treatment-naïve and treatment-experienced (without darunavir resistance-associated mutations [RAMs]) individuals, and has been evaluated in phase 2/3 studies with durations between 48 and 192 weeks. OBJECTIVE: To summarize the development (or identification) of post-baseline resistance (RAMs and antiretroviral phenotypic susceptibility) among subjects receiving darunavir QD dosing. METHODS: Seven phase 2/3 studies with available genotypes/phenotypes for subjects treated with ritonavir- or cobicistat-boosted darunavir 800 mg QD regimens were assessed: ARTEMIS (NCT00258557; n = 343), GS-US-299-0102 (NCT01565850; n = 153), GS-US-216-0130 (NCT01440569; n = 313), ODIN (NCT00524368; n = 294), INROADS (NCT01199939; n = 54), MONET (NCT00458302; n = 256), and PROTEA (NCT01448707; n = 273)...
November 16, 2017: HIV Clinical Trials
https://www.readbyqxmd.com/read/29142953/absence-of-hiv-associated-nephropathy-among-antiretroviral-naive-adults-with-persistent-albuminuria-in-western-kenya
#20
M K Koech, M O G Owiti, W D Owino-Ong'or, A K Koskei, M J Karoney, V D D'Agati, C M Wyatt
Introduction: HIV-associated nephropathy (HIVAN) has been strongly linked to African ancestry. However, studies have demonstrated wide variability in the prevalence of HIVAN in different sub-Saharan African populations. Accurate assessment of the disease burden is important because antiretroviral therapy (ART) is increasingly available and may prevent progression to end-stage renal disease. Methods: We prospectively screened ART-naïve, afebrile, nonhypertensive, and nondiabetic adults attending a large HIV care program in Western Kenya for the presence of albuminuria (dipstick albumin ≥ trace or urine albumin to creatinine ratio [UACR] ≥ 30 mg/g)...
March 2017: KI Reports
keyword
keyword
32845
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"